xRead - Globus and Chronic Cough (April 2024)

Wamkpah et al.

Page 11

CONCLUSION

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

Our meta-analysis described various treatments for NC, introduced future potential for procedural therapy, and highlighted areas for improving diagnosis of NC, such as strict adherence to CHEST guidelines or sophisticated non-acid reflux testing to rule out reflux associated disease. NC is a frustrating condition for patients and physicians, who are often shuffling different medication trials with unclear certainty of improvement. Standardized reporting of outcomes for NC is critically important to inform clinicians, patients, and researchers managing this challenging clinical scenario.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGMENTS

Research reported in this publication was supported by the National Institute of Deafness and Other Communication Disorders within the National Institutes of Health (NIH) under Award Number 5T32DC000022 and by the National Center for Advancing Translational Sciences of the NIH under Award Number UL1TR002345. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

The authors have no other funding, financial relationships, or conflicts of interest to disclose.

REFERENCES

1. Song WJ, Chang YS, Faruqi S, et al. The global epidemiology of chronic cough in adults: a systematic review and meta-analysis. Eur Respir J 2015;45:1479–1481. [PubMed: 25657027] 2. Bastian ZJ, Bastian RW. The use of neuralgia medications to treat sensory neuropathic cough: our experience in a retrospective cohort of thirty-two patients. PeerJ 2015;3:2015. 3. Altman KW, Noordzij JP, Rosen CA, Cohen S, Sulica L. Neurogenic cough. Laryngoscope 2015;125:1675–1681. [PubMed: 25647253] 4. Hoppo T, Komatsu Y, Jobe BA. Antireflux surgery in patients with chronic cough and abnormal proximal exposure as measured by hypopharyngeal multichannel intraluminal impedance. JAMA Surg 2013;148:608–605. [PubMed: 23700139] 5. Gibson P, Wang G, McGarvey L, Vertigan AE, Altman KW, Birring SS. Treatment of unexplained chronic cough: CHEST guideline and expert panel report. Chest 2016;149:27–44. [PubMed: 26426314] 6. Lewis SZ, Diekemper R, Ornelas J, Casey KR. Methodologies for the development of CHEST guidelines and expert panel reports. Chest 2014;146: 182–192. [PubMed: 25010961] 7. Ryan NM, Gibson PG. Gabapentin for idiopathic chronic cough: a randomised controlled trial. Lung 2012;190:64. 8. DePietro JD, Stein DJ, Calloway N, Cohen SM, Noordzij PJ. U.S. practice variations in the treatment of chronic laryngopharyngeal neuropathy. Laryngoscope 2014;124:955–960. [PubMed: 24122867] 9. Ryan NM, Vertigan AE, Birring SS. An update and systematic review on drug therapies for the treatment of refractory chronic cough. Expert Opin Pharmacother 2018;19:687–711. [PubMed: 29658795] 10. Chamberlain S, Birring SS, Garrod R. Nonpharmacological interventions for refractory chronic cough patients: systematic review. Lung 2014;192: 75–85. [PubMed: 24121952] 11. Dhillon VK. Superior laryngeal nerve block for neurogenic cough: a case series. Laryngoscope Investig Otolaryngol 2019;4:410–413.

Laryngoscope . Author manuscript; available in PMC 2022 January 01.